Dr. Deshen Wang 王德深
Chief Physician, Lecturer
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of digestive system tumors, including colorectal, gastroesophageal, biliary-pancreatic, and gastrointestinal neuroendocrine tumors. Focuses on new drug development and basic translational research.
Dr. Wang holds an MD and serves as a Chief Physician and doctoral supervisor. Research focuses on medical oncology and translational studies for digestive tumors. Dr. Wang has led projects funded by the National Natural Science Foundation of China and published over 20 papers in journals such as Gut and JAMA Oncol. Findings are included in CSCO guidelines and the UpToDate database. Dr. Wang serves as a reviewer for American Journal of Gastroenterology and eBioMedicine.
Professional roles
- Member, Professional Committee on Clinical Chemotherapy, China Anti-Cancer Association
- Standing Committee Member, Youth Committee for Molecular Targeted Therapy and Colorectal Cancer, Guangdong Anti-Cancer Association
- Standing Committee Member, Gastrointestinal Tumor Branch, Guangdong Precision Medicine Application Association
- Editorial Board Member, Drug Resistance Updates
Name order: in Chinese the family name comes first (Wang Deshen). Papers usually list the name as Deshen Wang or Wang D.
Selected publications
108 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Med, 2026 (first author): Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial. PubMed 42723578
- Ther Adv Med Oncol, 2026 (senior author): A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases. PubMed 41567811
- HPB (Oxford), 2025 (senior author): Percutaneous hepatic artery infusion chemotherapy with oxaliplatin and fluoropyrimidines in treatment-resistant colorectal cancer patients with unresectable liver metastases: a retrospective cohort study. PubMed 39668070
- Eur J Cancer, 2025 (first author): Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. PubMed 39644535
- NPJ Precis Oncol, 2024 (senior author): Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis. PubMed 38740834
- PLoS Med, 2024 (first author): Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PubMed 38728364
- Ther Adv Med Oncol, 2024 (senior author): Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. PubMed 38205077
- Drug Resist Updat, 2022 (senior author): Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. PubMed 36202008
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion